Citigroup
SGMT icon

Citigroup’s Sagimet Biosciences SGMT Stock Holding History

Citigroup’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71K Sell
13,586
-4,390
-24% -$24.5K ﹤0.01% 4397
2025
Q4 		$106K Buy
+17,976
New +$129K ﹤0.01% 4296
2025
Q3 		– Sell
-3,631
Closed -$27.7K – 6294
2025
Q2 		$27.7K Buy
+3,631
New +$15.3K ﹤0.01% 4999
2025
Q1 		– Sell
-111,208
Closed -$500K – 5918
2024
Q4 		$500K Sell
111,208
-5,522
-5% -$28K ﹤0.01% 3826
2024
Q3 		$323K Sell
116,730
-19,014
-14% -$58.6K ﹤0.01% 4027
2024
Q2 		$464K Buy
135,744
+130,735
+2,610% +$600K ﹤0.01% 3444
2024
Q1 		$27.1K Buy
5,009
+4,151
+484% +$29.8K ﹤0.01% 4931
2023
Q4 		$4.65K Buy
+858
New +$4.05K ﹤0.01% 5343

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's SGMT Position: Q1 2026 in Review

Citigroup reduced its Sagimet Biosciences (SGMT) stake by 24% in Q1 2026, selling an estimated $24.5K and leaving 13,586 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #4397.

Citigroup first reported a position in SGMT in Q4 2023 and has held it in 8 quarters since. The position peaked at $500K in Q4 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Citigroup held 13,586 shares of Sagimet Biosciences worth $71K as of Q1 2026.
  • Citigroup sold 4,390 Sagimet Biosciences shares in Q1 2026, an estimated $24.5K.
  • Sagimet Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4397 holding.
  • Citigroup first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 8 quarters since.
  • Citigroup's Sagimet Biosciences position peaked at $500K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.